GET DAILY SIGNALSALX Oncology (ALXO) Rebounds +13% Over 30 Days After Hitting Multi-Year Low
Key Takeaways
- ALX Oncology (ALXO) shares have climbed roughly +13% over the last 30 days, rebounding from a multi-year low near $0.86 reached in mid-October 2026.
- The move follows a sharp September-to-mid-October selloff triggered by a dilutive pre-funded warrant exchange agreement disclosed on October 15, 2026.
- ALX Oncology is a clinical-stage immuno-oncology company; its lead asset, evorpacept, is being developed in combination with partners including Jazz Pharmaceuticals.
- Wall Street consensus remains a Strong Buy, with an average price target near $4.60 versus a recent share price around $1.38.
- Over the last quarter, the stock is still down roughly 29%, reflecting persistent dilution and cash-burn concerns.
- Key catalysts ahead include the ASPEN-09-Breast topline readout expected in mid-2027 and ALX2004 dose-escalation safety data in the second half of 2026.
- For additional detail, explore ALXO's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how AI-driven trading systems are approaching this ticker.
A Closer Look at ALX Oncology and Its Position
ALX Oncology Holdings Inc. (ALXO) is a clinical-stage biotechnology company based in South San Francisco. It develops cancer therapies that pair its lead candidate with established treatments. The main asset, evorpacept, blocks CD47 and is designed to work alongside anti-cancer antibodies, ADCs, and checkpoint inhibitors. A second program, ALX2004, targets EGFR as an ADC. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Investors track ALXO because evorpacept has shown promise in certain HER2-positive cancers, and the company is advancing its ASPEN-09-Breast Phase 2 trial. Partners include Jazz Pharmaceuticals, Merck, and Sanofi. As a pre-revenue biotech, valuation hinges largely on clinical readouts.
Stock Performance Over the Past 30 Days and Quarter
In the last 30 days, ALXO shares rose about +13%, moving from near $1.22 early in October to around $1.38 in early November. The path included a drop to a multi-year low near $0.86 in mid-October, followed by a recovery exceeding 50% from that point.
The quarter tells a different story. Three months ago the stock traded near $1.94; at the current level around $1.38, that represents a decline of roughly 29%. The recent rebound has only partly offset earlier losses tied to financing concerns.
What Pushed the Stock Higher in Recent Weeks
The main driver was a mid-October financing move. On October 14, 2026, the company reached exchange agreements with certain stockholders, including funds tied to Blackstone, RA Capital, and venBio. They surrendered about 13.35 million shares for an equal number of pre-funded warrants at a $0.001 exercise price. The 8-K filing on October 15 triggered a negative reaction and the low near $0.86.
Analyst support helped the recovery. H.C. Wainwright kept a Buy rating and $4.00 target on October 1, while Wells Fargo maintained Buy with a $5.00 target on October 16. Consensus stays at Strong Buy with an average target near $4.60. From what I see, bargain buying in a low-float name supported the rebound even as broader markets turned cautious.
The Quarterly Decline and Lingering Pressures
The wider drop reflects ongoing cash-burn and dilution worries typical for a pre-revenue clinical biotech. Despite a narrower Q2 2026 net loss and a cash runway into the first half of 2028, investors remain focused on future financing needs. A $150 million offering closed in February 2026 at $1.57 per share, and the October exchange added to the overhang. Technical signals also weakened when the 50-day moving average crossed below the 200-day in early October.
Key Events to Watch Going Forward
Topline data from the Phase 2 ASPEN-09-Breast trial (about 80 patients) is expected in mid-2027. Dose-escalation safety results for ALX2004 are due in the second half of 2026. The next earnings report, likely in early-to-mid November 2026, will update spending and cash position. Macro factors such as interest rates and biotech risk appetite, along with any new financing, will also matter. Trial outcomes remain the biggest binary risks.
AI Tools in My Ongoing Research
I frequently review Tickeron’s AI Trading Bots to understand how different automated strategies are positioned on names like this one. The platform highlights top-performing bots across various timeframes and approaches, giving a data-driven view of algorithmic activity in the biotech space without depending on any single signal. This helps round out my own analysis of event-driven stocks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALXO's RSI Indicator climbs out of oversold territory
The RSI Indicator for ALXO moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 44 similar instances when the indicator left oversold territory. In 40 of the 44 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ALXO as a result. In 70 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for ALXO just turned positive on October 19, 2026. Looking at past instances where ALXO's MACD turned positive, the stock continued to rise in 27 of 40 cases over the following month. The odds of a continued upward trend are 68%.
Following a +10.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALXO advanced for three days, in 212 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 50-day moving average for ALXO moved below the 200-day moving average on October 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALXO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ALXO broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALXO entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. ALXO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.310) is normal, around the industry mean (3.104). P/E Ratio (-1.122) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALXO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical stage company, which engages in the research and development of therapies for cancer patients
Industry Biotechnology
Advertisement